| 1. |
|
|
| 2. |
|
|
| 3. |
- Brandt, J. R., et al.
(författare)
-
Liv og død i Hierapolis. Norske utgravninger i en hellenistisk–romersk–bysantinsk by i Lilleasia
- 2016
-
Ingår i: Viking. - : University of Oslo Library. - 0332-608X .- 2535-2660. ; 79, s. 193-220
-
Tidskriftsartikel (refereegranskat)abstract
- Life and Death at Hierapolis. Norwegian excavations in a Hellenistic–Roman– Byzantine town in Asia Minor From 2007 to 2015 the University of Oslo, invited by The Italian Archaeological Mission at Hierapolis in Phrygia, conducted archaeological research in the North-East Necropolis at Hierapolis. The aim of the project was to document all visible tombs and sarcophagi of the necropolis and excavate selected tomb areas and tombs. The research, including osteological, DNA- and isotope-analyses, investigated the life of the inhabitants over a long period of time (ca. 100–1300 A.C.) with reference to tomb architecture, landscape perception, organization, entrepreneurship, ritual practices, genetic relations and origins, demography, health, sickness, diets, and individual movement patterns. Many of the aims are answered in the article, here shall only be mentioned two important discoveries: cremation has been documented as late as the 5th/6th centuries A.C., in periods of crisis perhaps used to signal pagan opposition to imposed Christian practices; the life conditions in the Roman/ Early Byzantine period were much better than in that of the Middle Byzantine period.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Cappelletto, Chiara, et al.
(författare)
-
Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
- 2023
-
Ingår i: European Journal of Heart Failure. - : WILEY. - 1388-9842 .- 1879-0844. ; 25:5, s. 698-710
-
Tidskriftsartikel (refereegranskat)abstract
- Aims To investigate the use of guideline-directed medical therapies (GDMT) and associated outcomes in obese (body mass index >= 30 kg/m(2)) versus non-obese patients with heart failure (HF) with reduced ejection fraction (HFrEF). Methods and results Patients with HFrEF from the Swedish HF Registry were included. Of 16 116 patients, 24% were obese. In obese versus non-obese patients, use of treatments was 91% versus 86% for renin-angiotensin system inhibitors (RASi)/angiotensin receptor-neprilysin inhibitors (ARNi), 94% versus 91% for beta-blockers, 53% versus 43% for mineralocorticoid receptor antagonists. Obesity was shown to be independently associated with more likely use of each treatment, triple combination therapy, and the achievement of target dose by multivariable logistic regressions. Multivariable Cox regressions showed use of RASi/ARNi and beta-blockers being independently associated with lower risk of all-cause/cardiovascular death regardless of obesity, although, when considering competing risks, a lower risk of cardiovascular death with RASi/ARNi in obese versus non-obese patients was observed. RASi/ARNi were associated with lower risk of HF hospitalization in obese but not in non-obese patients, whereas beta-blockers were not associated with the risk of HF hospitalization regardless of obesity. At the competing risk analysis, RASi/ARNi use was associated with higher risk of HF hospitalization regardless of obesity. Conclusion Obese patients were more likely to receive optimal treatments after adjustment for factors affecting tolerability, suggesting that perceived beyond actual tolerance issues limit GDMT implementation. RASi/ARNi and beta-blockers were associated with lower mortality regardless of obesity, with a greater association between RASi/ARNi and lower cardiovascular death in obese versus non-obese patients when considering competing risk.
|
|
| 10. |
- Cappelletto, Elia, et al.
(författare)
-
Impact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User Centricity
- 2024
-
Ingår i: Journal of Pharmaceutical Sciences. - : Elsevier B.V.. - 0022-3549 .- 1520-6017.
-
Forskningsöversikt (refereegranskat)abstract
- This article evaluates the current gaps around the impact of post-manufacturing processes on the product qualities of protein-based biologics, with a focus on user centricity. It includes the evaluation of the regulatory guidance available, describes a collection of scientific literature and case studies to showcase the impact of post-manufacturing stresses on product and dosing solution quality. It also outlines the complexity of clinical handling and the need for communication, and alignment between drug providers, healthcare professionals, users, and patients. Regulatory agencies provide clear expectations for drug manufacturing processes, however, guidance supporting post-product manufacturing handling is less defined and often misaligned. This is problematic as the pharmaceutical products experience numerous stresses and processes which can potentially impact drug quality, safety and efficacy. This article aims to stimulate discussion amongst pharmaceutical developers, health care providers, device manufacturers, and public researchers to improve these processes. Patients and caregivers' awareness can be achieved by providing relevant educational material on pharmaceutical product handling.
|
|
